title: The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A(4) receptor.
abstract: A D-methionine-containing peptide, Trp-Lys-Tyr-Met-Val-D-Met-NH(2) (WKYMVm), featuring a unique receptor specificity was investigated with respect to its ability to activate neutrophil effector functions. The peptide was found to be more potent than the N-formylated peptide N-formyl-Met-Leu-Phe (fMLF) at inducing neutrophil chemotaxis, mobilization of neutrophil complement receptor 3 (CR3), and activation of the neutrophil NADPH-oxidase. The fact that binding of fML[(3)H]F was inhibited by both fMLF and WKYMVm suggests that N-formyl peptide receptor (FPR) is shared by these peptides. However, the neutrophil response induced by the WKYMVm peptide was insensitive to the fMLF antagonists, cyclosporin H, and Boc-FLFLF that specifically block the function of the FPR. These results suggest that even though WKYMVm may bind FPR the cells are activated preferentially through a receptor distinct from the FPR. Using transfected HL-60 cells expressing either the FPR or its neutrophil homologue FPRL1, also referred to as LXA(4)R because it has been shown to bind lipoxin A(4), we show that WKYMVm is about 300-fold more active at mobilizing intracellular calcium through FPRL1 than through FPR. The WKYMVm activates FPRL1-expressing cells in a cyclosporin H-independent manner with an EC(50 )of around 75 pmol/L, whereas it activates FPR-expressing cells with an EC(50 )of around 25 nmol/L. The observation that exudated cells are primed in their response to WKYMVm suggests that FPRL1/LXA(4)R like FPR is stored in mobilizable organelles. (Blood. 2000;95:1810-1818)
authors.affiliation: The Phagocyte Research Laboratory, Department of Medical Microbiology and Immunology, University of Göteborg, Göteborg, Sweden. claes.dahlgren@microbio.gu.se
authors.forename: C
authors.initials: C
authors.lastname: Dahlgren
authors.forename: T
authors.initials: T
authors.lastname: Christophe
authors.forename: F
authors.initials: F
authors.lastname: Boulay
authors.forename: P N
authors.initials: PN
authors.lastname: Madianos
authors.forename: M J
authors.initials: MJ
authors.lastname: Rabiet
authors.forename: A
authors.initials: A
authors.lastname: Karlsson
mesh_terms: D002118:Calcium / Q000502:physiology; D002630:Chemotactic Factors / Q000494:pharmacology*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D016572:Cyclosporine / Q000494:pharmacology; D004790:Enzyme Induction / Q000187:drug effects; D018922:HL-60 Cells / Q000187:drug effects; D006801:Humans; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D019255:NADPH Oxidases / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects* / Q000502:physiology; D009842:Oligopeptides / Q000494:pharmacology*; D011956:Receptors, Cell Surface / Q000187:drug effects* / Q000502:physiology; D044042:Receptors, Formyl Peptide; D044067:Receptors, Lipoxin; D016897:Respiratory Burst / Q000187:drug effects; D014162:Transfection
chemical_list: D002630:Chemotactic Factors; C105101:FPR2 protein, human; D009842:Oligopeptides; D011956:Receptors, Cell Surface; D044042:Receptors, Formyl Peptide; D044067:Receptors, Lipoxin; C113617:Trp-Lys-Tyr-Met-Val-Met; C081709:tert-butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanyl-OH; D009240:N-Formylmethionine Leucyl-Phenylalanine; D016572:Cyclosporine; D019255:NADPH Oxidases; C050025:cyclosporin H; D002118:Calcium